Isoforms S and L of MRPL33 from alternative splicing have isoform‑specific roles in the chemoresponse to epirubicin in gastric cancer cells via the PI3K/AKT signaling pathway

Li,Jie; Feng,Dan; Gao,Cuixia; Zhang,Yingyi; Xu,Jing; Wu,Meihong; Zhan,Xianbao

doi:10.3892/ijo.2019.4728

Isoforms S and L of MRPL33 from alternative splicing have isoform‑specific roles in the chemoresponse to epirubicin in gastric cancer cells via the PI3K/AKT signaling pathway

Authors:
- Jie Li
- Dan Feng
- Cuixia Gao
- Yingyi Zhang
- Jing Xu
- Meihong Wu
- Xianbao Zhan
View Affiliations

Affiliations: Department of Oncology, The Changhai Hospital, Shanghai 200433, P.R. China, Department of Research and Development, The Shanghai Polaris Biology Technology, Shanghai 201203, P.R. China
Published online on: February 27, 2019 https://doi.org/10.3892/ijo.2019.4728
Pages: 1591-1600
Copyright: © Li et al. This is an open access article distributed under the terms of Creative Commons Attribution License [CC BY_NC 4.0].

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Drug resistance is a major cause of cancer‑associated mortality. Epirubicin‑based chemotherapy initially benefits patients with metastatic or advanced gastric cancer; however, tumor recurrence can occur following several courses of treatment. Mitochondrial ribosomal protein L33 (MRPL33)‑long (L) and MRPL33‑short (S), isoforms of MRPL33 that arise from AS, have been reported to regulate cell growth and apoptosis in cancer; however, few studies have evaluated the roles of MRPL33‑L and MRPL33‑S in gastric cancer. In the present study, MRPL33‑L was demonstrated to be significantly more abundant in gastric tumor tissues than the MRPL33‑S isoform. MRPL33‑S promoted chemosensitivity to epirubicin in gastric cancer as demonstrated by a chemoresponse assay; chemosensitivity was suppressed in response to MRPL33‑L. Gene microarray analysis was performed to investigate the underlying mechanisms. Bioinformatic analysis revealed that overexpression of MRPL33‑L and MRPL33‑S served critical roles in transcription, signal transduction and apoptosis. In particular, the phosphoinositide 3‑kinase (PI3K)/AKT serine/threonine kinase (AKT) signaling pathway was markedly regulated. A total of 36 target genes, including PIK3 regulatory subunit α, AKT2, cAMP response element‑binding protein (CREB) 1, forkhead box 3, glycogen synthase kinase 3β and mammalian target of rapamycin, which are involved in the PI3K/AKT signaling pathway, were selected for further investigation via protein‑protein interaction network and Kyoto Encyclopedia of Genes and Genomes pathway analyses. Furthermore, western blot analysis indicated that MRPL33‑S promoted the chemoresponse to epirubicin by deactivating PI3K/AKT/CREB signaling and inducing apoptosis, while MRPL33‑L had the opposite effects. In conclusion, the results of the present study revealed that isoforms S and L of MRPL33, which arise from alternative splicing, exhibited opposing roles in the chemoresponse to epirubicin in gastric cancer via the PI3K/AKT signaling pathway. These findings may contribute to the development of potential therapeutic strategies for the resensitization of patients with gastric cancer to epirubicin treatment.

View Figures

View References

1	Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J and Jemal A: Global cancer statistics, 2012. CA Cancer J Clin. 65:87–108. 2015. View Article : Google Scholar : PubMed/NCBI
2	Catenacci DVT, Tebbutt NC, Davidenko I, Murad AM, Al-Batran SE, Ilson DH, Tjulandin S, Gotovkin E, Karaszewska B, Bondarenko I, et al: Rilotumumab plus epirubicin, cisplatin, and capecitabine as first-line therapy in advanced MET-positive gastric or gastro-oesophageal junction cancer (RILOMET-1): A randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 18:1467–1482. 2017. View Article : Google Scholar : PubMed/NCBI
3	Iveson T, Donehower RC, Davidenko I, Tjulandin S, Deptala A, Harrison M, Nirni S, Lakshmaiah K, Thomas A, Jiang Y, et al: Rilotumumab in combination with epirubicin, cisplatin, and capecitabine as first-line treatment for gastric or oesophagogastric junction adenocarcinoma: An open-label, dose de-escalation phase 1b study and a double-blind, randomised phase 2 study. Lancet Oncol. 15:1007–1018. 2014. View Article : Google Scholar : PubMed/NCBI
4	Peng L, Yang W, Zhang Z, Liu H and Hua Y: Clinical features and prognosis analysis of 21 gastric cancer patients with pathological complete response after neoadjuvant chemotherapy. Zhonghua Wei Chang Wai Ke Za Zhi. 20:1168–1173. 2017.In Chinese. PubMed/NCBI
5	Polkowska-Pruszyńska B, Rawicz-Pruszyński K, Ciseł B, Sitarz R, Polkowska G, Krupski W and Polkowski WP: Liver metastases from gastric carcinoma: A Case report and review of the literature. Curr Probl Cancer. 41:222–230. 2017. View Article : Google Scholar
6	Oltean S and Bates DO: Hallmarks of alternative splicing in cancer. Oncogene. 33:5311–5318. 2014. View Article : Google Scholar
7	Siegfried Z and Karni R: The role of alternative splicing in cancer drug resistance. Curr Opin Genet Dev. 48:16–21. 2018. View Article : Google Scholar
8	Wojtuszkiewicz A, Assaraf YG, Maas MJ, Kaspers GJ, Jansen G and Cloos J: Pre-mRNA splicing in cancer: The relevance in oncogenesis, treatment and drug resistance. Expert Opin Drug Metab Toxicol. 11:673–689. 2015. View Article : Google Scholar
9	Dehm SM: mRNA splicing variants: Exploiting modularity to outwit cancer therapy. Cancer Res. 73:5309–5314. 2013. View Article : Google Scholar : PubMed/NCBI
10	Bonnal S, Vigevani L and Valcárcel J: The spliceosome as a target of novel antitumour drugs. Nat Rev Drug Discov. 11:847–859. 2012. View Article : Google Scholar : PubMed/NCBI
11	Kole R, Krainer AR and Altman S: RNA therapeutics: Beyond RNA interference and antisense oligonucleotides. Nat Rev Drug Discov. 11:125–140. 2012. View Article : Google Scholar : PubMed/NCBI
12	Hua Y, Sahashi K, Rigo F, Hung G, Horev G, Bennett CF and Krainer AR: Peripheral SMN restoration is essential for long-term rescue of a severe spinal muscular atrophy mouse model. Nature. 478:123–126. 2011. View Article : Google Scholar : PubMed/NCBI
13	Godfrey C, Desviat LR, Smedsrød B, Piétri-Rouxel F, Denti MA, Disterer P, Lorain S, Nogales-Gadea G, Sardone V, Anwar R, et al: Delivery is key: Lessons learnt from developing splice-switching antisense therapies. EMBO Mol Med. 9:545–557. 2017. View Article : Google Scholar : PubMed/NCBI
14	Gopisetty G and Thangarajan R: Mammalian mitochondrial ribosomal small subunit (MRPS) genes: A putative role in human disease. Gene. 589:27–35. 2016. View Article : Google Scholar : PubMed/NCBI
15	Kim HJ, Maiti P and Barrientos A: Mitochondrial Ribosomes in Cancer. Semin Cancer Biol. 47:67–81. 2017. View Article : Google Scholar : PubMed/NCBI
16	Liu L, Luo C, Luo Y, Chen L, Liu Y, Wang Y, Han J, Zhang Y, Wei N, Xie Z, et al: MRPL33 and its splicing regulator hnRNPK are required for mitochondria function and implicated in tumor progression. Oncogene. 37:86–94. 2018. View Article : Google Scholar
17	Liu T, Sun H, Zhu D, Dong X, Liu F, Liang X, Chen C, Shao B, Wang M, Wang Y, et al: TRA2A Promoted Paclitaxel Resistance and Tumor Progression in Triple-Negative Breast Cancers via Regulating Alternative Splicing. Mol Cancer Ther. 16:1377–1388. 2017. View Article : Google Scholar : PubMed/NCBI
18	Li J, Wang J, Yu J, Zhao Y, Dong Y, Fan Y, Li N, Zhang Y and Wang Y: Knockdown of POLE2 expression suppresses lung adenocarcinoma cell malignant phenotypes in vitro. Oncol Rep. 40:2477–2486. 2018.PubMed/NCBI
19	Chen S, Zhang L, Su Y and Zhang X: Screening potential biomarkers for colorectal cancer based on circular RNA chips. Oncol Rep. 39:2499–2512. 2018.PubMed/NCBI
20	Howe EA, Sinha R, Schlauch D and Quackenbush J: RNA-Seq analysis in MeV. Bioinformatics. 27:3209–3210. 2011. View Article : Google Scholar : PubMed/NCBI
21	Sun S, Wang Y, Wu Y, Gao Y, Li Q, Abdulrahman AA, Liu XF, Ji GQ, Gao J, Li L, et al: Identification of COL1A1 as an invasion related gene in malignant astrocytoma. Int J Oncol. 53:2542–2554. 2018.PubMed/NCBI
22	Ge Y, Weygant N, Qu D, May R, Berry WL, Yao J, Chandrakesan P, Zheng W, Zhao L, Zhao KL, et al: Alternative splice variants of DCLK1 mark cancer stem cells, promote self-renewal and drug-resistance, and can be targeted to inhibit tumorigenesis in kidney cancer. Int J Cancer. 143:1162–1175. 2018. View Article : Google Scholar : PubMed/NCBI
23	Wan L, Yu W, Shen E, Sun W, Liu Y, Kong J, Wu Y, Han F, Zhang L, Yu T, et al: SRSF6-regulated alternative splicing that promotes tumour progression offers a therapy target for colorectal cancer. Gut. 68:118–129. 2019. View Article : Google Scholar
24	Smith LD, Leme de Calais F, Raponi M, Mellone M, Buratti E, Blaydes JP and Baralle D: Novel splice-switching oligonucleotide promotes BRCA1 aberrant splicing and susceptibility to PARP inhibitor action. Int J Cancer. 140:1564–1570. 2017. View Article : Google Scholar
25	Le KQ, Prabhakar BS, Hong WJ and Li LC: Alternative splicing as a biomarker and potential target for drug discovery. Acta Pharmacol Sin. 36:1212–1218. 2015. View Article : Google Scholar : PubMed/NCBI
26	Anderson GR, Wardell SE, Cakir M, Yip C, Ahn YR, Ali M, Yllanes AP, Chao CA, McDonnell DP and Wood KC: Dysregulation of mitochondrial dynamics proteins are a targetable feature of human tumors. Nat Commun. 9:16772018. View Article : Google Scholar : PubMed/NCBI
27	Chen A, Tiosano D, Guran T, Baris HN, Bayram Y, Mory A, Shapiro-Kulnane L, Hodges CA, Akdemir ZC, Turan S, et al: Mutations in the mitochondrial ribosomal protein MRPS22 lead to primary ovarian insufficiency. Hum Mol Genet. 27:1913–1926. 2018. View Article : Google Scholar : PubMed/NCBI
28	Richter U, Lahtinen T, Marttinen P, Myöhänen M, Greco D, Cannino G, Jacobs HT, Lietzén N, Nyman TA and Battersby BJ: A mitochondrial ribosomal and RNA decay pathway blocks cell proliferation. Curr Biol. 23:535–541. 2013. View Article : Google Scholar : PubMed/NCBI
29	Hao C, Duan H, Li H, Wang H, Liu Y, Fan Y and Zhang C: Knockdown of MRPL42 suppresses glioma cell proliferation by inducing cell cycle arrest and apoptosis. Biosci Rep. 38:BSR201714562018. View Article : Google Scholar : PubMed/NCBI
30	Bijur GN and Jope RS: Rapid accumulation of Akt in mitochondria following phosphatidylinositol 3-kinase activation. J Neurochem. 87:1427–1435. 2003. View Article : Google Scholar
31	Vivanco I, Chen ZC, Tanos B, Oldrini B, Hsieh WY, Yannuzzi N, Campos C and Mellinghoff IK: A kinase-independent function of AKT promotes cancer cell survival. eLife. 3:e037512014. View Article : Google Scholar
32	Agarwal E, Brattain MG and Chowdhury S: Cell survival and metastasis regulation by Akt signaling in colorectal cancer. Cell Signal. 25:1711–1719. 2013. View Article : Google Scholar : PubMed/NCBI
33	Nath S and Mandal C, Chatterjee U and Mandal C: Association of cytosolic sialidase Neu2 with plasma membrane enhances Fas-mediated apoptosis by impairing PI3K-Akt/mTOR-mediated pathway in pancreatic cancer cells. Cell Death Dis. 9:2102018. View Article : Google Scholar : PubMed/NCBI
34	Suyama K, Yao J, Liang H, Benard O, Loudig OD, Amgalan D, McKimpson WM, Phillips GR, Segall J, Wang Y, et al: An Akt3 Splice Variant Lacking the Serine 472 Phosphorylation Site Promotes Apoptosis and Suppresses Mammary Tumorigenesis. Cancer Res. 78:103–114. 2018. View Article : Google Scholar
35	Li T, Zhao X, Mo Z, Huang W, Yan H, Ling Z and Ye Y: Formononetin promotes cell cycle arrest via downregulation of Akt/Cyclin D1/CDK4 in human prostate cancer cells. Cell Physiol Biochem. 34:1351–1358. 2014. View Article : Google Scholar : PubMed/NCBI
36	Zhang H, Xu W, Li B, Zhang K, Wu Y, Xu H, Wang J, Zhang J, Fan R and Wei J: Curcumin Promotes Cell Cycle Arrest and Inhibits Survival of Human Renal Cancer Cells by Negative Modulation of the PI3K/AKT Signaling Pathway. Cell Biochem Biophys. 73:681–686. 2015. View Article : Google Scholar
37	Wei J and Wu J, Xu W, Nie H, Zhou R, Wang R, Liu Y, Tang G and Wu J: Salvianolic acid B inhibits glycolysis in oral squamous cell carcinoma via targeting PI3K/AKT/HIF-1α signaling pathway. Cell Death Dis. 9:5992018. View Article : Google Scholar
38	Avanzato D, Pupo E, Ducano N, Isella C, Bertalot G, Luise C, Pece S, Bruna A, Rueda OM, Caldas C, et al: High USP6NL levels in breast cancer sustain chronic AKT phosphorylation and GLUT1 stability fueling aerobic glycolysis. Cancer Res. 78:3432–3444. 2018.PubMed/NCBI
39	Haas B, Klinger V, Keksel C, Bonigut V, Kiefer D, Caspers J, Walther J, Wos-Maganga M, Weickhardt S, Röhn G, et al: Inhibition of the PI3K but not the MEK/ERK pathway sensitizes human glioma cells to alkylating drugs. Cancer Cell Int. 18:692018. View Article : Google Scholar : PubMed/NCBI
40	Ahn KC, Choi JY, Kim JS, Hwang SG, Kim WJ, Park JK and Um HD: ICAM-3 endows anticancer drug resistance against microtubule-damaging agents via activation of the ICAM-3-AKT/ERK-CREB-2 pathway and blockage of apoptosis. Biochem Biophys Res Commun. 441:507–513. 2013. View Article : Google Scholar : PubMed/NCBI
41	Park EJ, Min KJ, Choi KS and Kwon TK: Dicoumarol sensitizes renal cell carcinoma Caki cells to TRAIL-induced apoptosis through down-regulation of Bcl-2, Mcl-1 and c-FLIP in a NQO1-independent manner. Exp Cell Res. 323:144–154. 2014. View Article : Google Scholar : PubMed/NCBI